Comparative Outcomes of Treosulfan- versus Busulfan-Based Clofarabine Reduced Intensity Conditioning Regimens in Adult Allogeneic Transplant for Myeloid Malignancies
Posted inHematology-Oncology news

Comparative Outcomes of Treosulfan- versus Busulfan-Based Clofarabine Reduced Intensity Conditioning Regimens in Adult Allogeneic Transplant for Myeloid Malignancies

This retrospective study compares treosulfan and busulfan combined with clofarabine as reduced intensity conditioning before allogeneic transplant in adults with myeloid malignancies, highlighting faster neutrophil recovery and improved survival metrics with treosulfan.
Real-World Impact of Post-Treatment Circulating Tumor DNA Monitoring in Large B-Cell Lymphoma Using an Immunoglobulin-Based Assay
Posted inHematology-Oncology news Oncology

Real-World Impact of Post-Treatment Circulating Tumor DNA Monitoring in Large B-Cell Lymphoma Using an Immunoglobulin-Based Assay

This study demonstrates that detection of circulating tumor DNA (ctDNA) after treatment in large B-cell lymphoma predicts progression-free survival, highlighting the clinical utility of a rapid immunoglobulin rearrangement-targeted assay for measurable residual disease assessment in real-world settings.
ATG Versus ATG Plus Post-Transplant Cyclophosphamide: A Pilot Trial for GvHD Prophylaxis in Matched Donor Hematopoietic Cell Transplants
Posted inHematology-Oncology news

ATG Versus ATG Plus Post-Transplant Cyclophosphamide: A Pilot Trial for GvHD Prophylaxis in Matched Donor Hematopoietic Cell Transplants

A randomized pilot trial shows comparable survival and safety outcomes for anti-thymocyte globulin alone versus combined with post-transplant cyclophosphamide, supporting further phase III investigation for graft-versus-host disease prophylaxis in matched donor hematopoietic cell transplantation.
Health Status Impairments in Tyrosine Kinase Inhibitor-Treated Chronic Myeloid Leukemia Patients Compared with Blood or Marrow Transplant Survivors and Non-Cancer Controls: A Clinical Review
Posted inClinical Updates Hematology-Oncology news

Health Status Impairments in Tyrosine Kinase Inhibitor-Treated Chronic Myeloid Leukemia Patients Compared with Blood or Marrow Transplant Survivors and Non-Cancer Controls: A Clinical Review

This review synthesizes evidence on health status impairments in long-term TKI-treated CML survivors relative to BMT survivors and non-cancer controls, emphasizing rates of functional impairment, activity limitation, frailty, and quality of life impacts, highlighting the necessity for vigilant survivorship care.
Histidine-Rich Glycoprotein as a Modulator of Platelet Adhesion and Aggregation: Mechanistic Insights and Clinical Implications
Posted inClinical Updates Hematology-Oncology Internal Medicine news

Histidine-Rich Glycoprotein as a Modulator of Platelet Adhesion and Aggregation: Mechanistic Insights and Clinical Implications

Histidine-rich glycoprotein (HRG) directly modulates platelet adhesion and aggregation by binding platelet receptors GPIbα and GPIIb/IIIa, competing with key ligands VWF and fibrinogen, thus attenuating thrombus formation; reduced HRG in sepsis and COVID-19 correlates with heightened platelet reactivity.